Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
risperidone + vitamin B12
- Development stage
- Preclinical
- Lead developer
- Johnson & Johnson
- Modality
- Small Molecules
- Administration
- Oral, Intramuscular
01
Overview
A therapeutic combination of risperidone, an atypical antipsychotic medication, and vitamin B12 (cyanocobalamin). This combination has been studied for its potential benefits in treating psychotic symptoms, particularly in Alzheimer's disease patients. Research suggests that vitamin B12 supplementation alongside antipsychotic drugs like risperidone may help reduce proinflammatory cytokines and increase anti-inflammatory cytokines, potentially improving psychotic symptoms. Additionally, vitamin B12 may help address some side effects associated with antipsychotic treatment.
02
Targets
DRD2 (Dopamine D2 Receptor)HTR2A (Serotonin receptor 5-HT2A)
Beyond the preview
Go deeper on risperidone + vitamin B12.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on risperidone + vitamin B12.